Johnson & Johnson colon inflammation drug sees 55% remission rates
Johnson & Johnson colon inflammation drug sees 55% remission rates
Read moreThu, 24th Oct 2019 08:09
Johnson & Johnson colon inflammation drug sees 55% remission rates
Read moreTRADING UPDATES: Cohort wins Italian navy contract; Beximco waits
Read moreTRADING UPDATES: Topps Tiles improves as curbs ease; Bermele makes buy
Read moreIN BRIEF: Director Scardino buys 10,000 PureTech Health shares
Read moreDIRECTOR DEALINGS: Melrose non-exec buys shares; TBC director sells
Read moreTRADING UPDATES: Marlowe turns to loss; AFC Energy sees maiden revenue
Read moreIN BRIEF: PureTech buys remaining 22% stake in Alivio Therapeutics
Read moreIN BRIEF: PureTech Health's Akili secures USD160 million in financing
Read moreEXECUTIVE CHANGES: Ebiquity appoints ITV executive Izlan to board
Read moreTRADING UPDATES: Serica production slips; Epwin confident for future
Read more(Sharecast News) - Biotechnology company Puretech Health said on Thursday that it had narrowed operating losses in 2020 on the back of a reduction in general and administrative expenses and a modest increase in full-year revenues.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIN BRIEF: PureTech Health's Akili to study AKL-T01 in Covid survivors
Read moreTRADING UPDATES: Contango in offtake talks for coking coal in Zimbabwe
Read moreEXECUTIVE CHANGES: Sureserve executive chair departs after turnaround
Read more